Pfizer (PFE) Tops Q1 EPS by 15c, Guidance Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Pfizer Reports First-Quarter 2022 Results
May 3, 2022 6:45 AM EDTFirst-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted Diluted EPS(3) of $1.62 Both Reported(2) and Adjusted(3) Diluted EPS Include a $0.05 Negative Impact for Acquired In-Process R&D Expenses(4), Which Prior to First-Quarter 2022 Had Largely Been Excluded From Adjusted(3) Results Reaffirms Full-Year 2022 Financial Guidance(4) for Revenues of $98.0 to $102.0 Billion, Which Includes Operational Increases Offset by Approximately $2 Billion of Negative Foreign Exchange Impacts Reaffirms 2022 Revenue Guidance for Comirnaty(1) of Approximately $32 Billion, Despite a ~$1 Billion... More
